Advertisement

Topics

Latest Proteomics NewsRSS

11:48 EDT 24th September 2017 | BioPortfolio

Study Published In /i> Regarding Prognostic And Cancer-Care Planning Value Of Biodesix, Inc.???s Veristrat Proteomic Test

  Life Sciences Jobs   ...

Study Published In Managed Care Regarding Prognostic and Cancer-Care Planning Value of Biodesix’s VeriStrat® Proteomic Test

BOULDER, Colo., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Findings published in the peer-reviewed journal Managed Care showed that prognostic information provided by the Biodesix® VeriStrat test can improve care for lung cancer patients and assist physicians in meeting several quality measures associated with the

Parasite Linked with Alzheimer's and Parkinson's Diseases, Epilepsy, and Cancer

About a third of the world’s population is chronically infected with the protozoan parasite Toxoplasma gondii . Data from the U.S. Centers for Disease Control and Prevention (CDC) suggest that about 11% of the U.S. population aged 6 years and over is infected with the parasite, while in other countries the infection rate has been shown to be up to 95%. Researchers from 16 institutions across...

Toxoplasma Linked with Alzheimer's and Parkinson's Diseases, Epilepsy, and Cancer

About a third of the world’s population is chronically infected with the protozoan parasite, Toxoplasma gondii . Figures from the U.S. Centers for Disease Control and Prevention (CDC) suggest that about 11 % of the U.S. population aged 6 years and over is infected with the parasite, while in other countries the infection rate has been shown to be up to 95%. Researchers from 16 institutions a...

Proteomics Technologies, Markets and Companies [Report Updated: 08092017] Prices from USD $5000

SummaryThis report describes and evaluates the proteomic technologies that will play an important role in drug discovery, molecular diagnostics and practice of medicine in the postgenomic era the first decade of the 21st century. Most commonly used technologies are 2D gel electrophoresis for protein separation and analysis of proteins by mass spectrometry. Microanalytical protein characterization...

Luminex Corporation Declares Third Quarter Cash Dividend

AUSTIN, Texas, Sept. 12, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the third quarter of 2017 of $0.06 per share of common stock payable on October 13, 2017 to stockholders of record as of the close of business on September 22, 2017. About Luminex CorporationAt Luminex, our...

Sigma-Aldrich (NASDAQ: SIAL) Declares $0.20 Quarterly Dividend

ST. LOUIS, Nov. 16, 2012 /PRNewswire/ -- The Board of Directors of Sigma-Aldrich Corporation (NASDAQ: SIAL) has approved a quarterly cash dividend of $0.20 per share.  The dividend is payable on December 14, 2012 to shareholders of record on November 30, 2012. About Sigma-Aldrich:  Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical and organic...

Chromatrap Announce Native ChIP Kit for Mass Spectrometry

Chromatrap announces that its popular Native ChIP kit is now fully compatible for mass spectrometry (MS) as a downstream process. Combining Chromatrap®’s unique solid-state ChIP technology with MS enables researchers to obtain high quality data sets for chromatin proteomic profiling and mapping of histone modification patterns....

Proteomics Identifies CKD Predictors

The investigators assessed proteomic profiling of 80 proteins using a multiplex assay.

Avant Diagnostics Acquires Exclusive Option to License Genetic Health Solution Technology Platform

GAITHERSBURG, Maryland, July 12, 2017 /PRNewswire/ -- Genetic Health Solution platform helps chronic disease patient management Patient-centric biomarker-based wellness programs designed to improve outcomes Avant Diagnostics, Inc. ("Avant") (OTC: AVDX), an oncology-focused Healthcare-IT company commercializing the proprietary Theralink® phospho-protein biomarker platform a...

Applied Proteomics Appoints Peter Klemm as CEO Following Series B Financing of $22.5 Million

SAN DIEGO, Feb. 7, 2012 /PRNewswire/ -- Applied Proteomics Inc. (API), powering the proteome to transform diagnostics, announced today the appointment of veteran diagnostic developer, Peter Klemm, Ph.D., as chief executive officer.  API also announced the move of the corporate headquarters to San Diego.  Prior to the move, API secured a $22.5 million Series B financing from D...

Autologous chondrocyte implantation-derived synovial fluids display distinct responder and non-responder proteomic profiles

Autologous chondrocyte implantation (ACI) can be used in the treatment of focal cartilage injuries to prevent the onset of osteoarthritis (OA). However, we are yet to understand fully why some individuals do n...

NantCell, a NantWorks Company, to Acquire Altor BioScience

Acquisition Price Represents Significant Premium to Recent Equity Financings NantCell, Inc., a member of the ecosystem of NantWorks companies, today announced that it has entered into a definitive merger agreement to acquire Altor BioScience Corporation. Under the terms of the merger agreement, each share of Altor BioScience capital stock will be ...

Avant Diagnostics Announces Confirmatory Clinical Utility Data for Theralink® in Pancreatic Cancer

GAITHERSBURG, Maryland, June 27, 2017 /PRNewswire/ -- - Theralink predicts 5-year survival for patients in response to standard of care - Negative predictive value allows physicians to change treatment decisions Avant Diagnostics, Inc. ('Avant') (OTC: AVDX), an oncology-focused healthcare technology company commercializing the proprietary Theralink® proteomic biomarker platform a...

Biotech Support Group Release: Research Poster Presented At The New Jersey Cancer Retreat For New Cancer Serum Biomarker Panel

MONMOUTH JUNCTION, NJ, June 7, 2017 -- Biotech Support Group presented a poster describing a biomarker panel of cancer dysregulation derived from serum proteomic profiles, at the New Jersey Cancer Retreat held on May 25, 2017 in New Brunswick, NJ. The poster authors and title are:Haiyan Zheng1; Swapan Roy2; Amenah Soherwardy1; Seema Rahman2; Matthew Kuruc2, 1Rutgers Center for...

Aviva Systems Biology Hires James Wang as Chief Operating Officer

SAN DIEGO, June 6, 2017 /PRNewswire/ -- Aviva Systems Biology Corporation (ASB), which supplies antibodies, proteins, ELISA kits and related-research products and services, has recruited Dr. Yi-Chun "James" Wang as its Chief Operating Officer. In this new role, Dr. Wang is tasked with accelerating ASB's growth through a combination of developing new products and expanding the service div...

NantOmics to Present Data on Using GPS Cancer Proteomic Analysis to Inform Metastatic Colorectal Cancer Patient Treatment with Temozolomide at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

Results to be presented during tumor biology session at the ASCO 2017 Annual Meeting NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular diagnostics and a member of the

NantOmics to Present Data on Using GPS Cancer Quantitative Proteomic Analysis of Class III B-Tubulin (TUBB3) to Predict Survival in Gastric Cancer Patients Randomized to Docetaxel at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

Results to be presented during gastrointestinal (noncolorectal) cancer session at the ASCO 2017 Annual Meeting NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in

LabKey Announces Newest Member of Panorama Partners Program

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) has become the newest member of the Panorama Partners Program. SEATTLE, WA (PRWEB) June 01, 2017 LabKey is pleased to announce that the National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) has become the newest member of the Panorama Partners Program, a collaboration of proteom...

Luminex Corporation To Present At Jefferies 2017 Global Healthcare Conference

AUSTIN, Texas, May 25, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Jefferies 2017 Global Healthcare Conference on Thursday, June 8 at 8:30am ET in New York. The investor presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at t...

Breast Cancer Liquid Biopsy Study Validates Test as Improved Diagnostic Tool

Noninvasive molecular diagnostic techniques are not only the latest cutting-edge technique to help clinicians improve disease prognosis—they are proving to be an essential element for the continued progression of precision medicine initiatives. Now, a team of investigators led by scientists at Provista Diagnostics has just released data from a new study demonstrating that a multiprotein biomarke...

Luminex Corporation Declares Second Quarter Cash Dividend

AUSTIN, Texas, May 24, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the second quarter of 2017 of $0.06 per share of common stock payable on July 14, 2017 to stockholders of record as of the close of business on June 23, 2017. About Luminex CorporationAt Luminex, our mission ...

New Study: Blood Test Offers Improved Breast Cancer Detection, New Tool to Reduce Use of Breast Biopsy

NEW YORK, May 23, 2017 /PRNewswire-USNewswire/ -- A new study published in Clinical Breast Cancer demonstrates that Videssa® Breast, a multi-protein biomarker blood test to detect breast cancer, can help inform better decision-making after abnormal mammogram or other breast imaging results and potentially reduce use of biopsy by up to 67 percent. The study evaluated the performance of Videssa Bre...

New Cell Atlas Shows Subcellular Distribution of 12,000 Proteins

Spatial demography—the spatial analysis of demographic processes—has long been used to derive insights from otherwise bewildering masses of data. Back in 1855, it was used by John Snow to identify the source of a cholera outbreak. More recently, it was taken up by the U.S. Census Bureau, which generates analyses indicating how government resources might be distributed across geographically def...

Hybrigenics (ALHYG) - Inecalcitol shows promise in CML, R&D refocus

Edison Investment Research - Pharmaceutical & healthcare - Hybrigenics: Hybrigenics’ main focus is the development of inecalcitol as a niche treatment for leukaemia. In February it presented encouraging initial results for inecalcitol in combination with oral imatinib in chronic myeloid leukaemia (CML), with 43% of patients responding in a Phase II study that will complete in H218. A Phase I...

Quick Search
Advertisement
 

review and buy Proteomics market research data and corporate reports here